Skip to main content
Top
Published in: Rheumatology International 6/2020

01-06-2020 | Coronavirus | Cases with a Message

Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs

Authors: Jehun Song, Seongmin Kang, Seung Won Choi, Kwang Won Seo, Sunggun Lee, Min Wook So, Doo-Ho Lim

Published in: Rheumatology International | Issue 6/2020

Login to get access

Abstract

In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase chain reaction (PCR). Chest X-ray showed increased opacity on the right lower lung area, and C-reactive protein level was slightly elevated. The patient was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine. Her symptoms and laboratory results gradually improved. Three weeks later, real-time PCR for COVID-19 showed negative conversion, and the patient was discharged without any complications.
Literature
2.
go back to reference Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R (2020) Features, evaluation and treatment coronavirus (COVID-19). StatPearls Publishing LLC., Treasure Island Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R (2020) Features, evaluation and treatment coronavirus (COVID-19). StatPearls Publishing LLC., Treasure Island
3.
go back to reference Listing J, Gerhold K, Zink A (2012) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 52:53–61CrossRef Listing J, Gerhold K, Zink A (2012) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 52:53–61CrossRef
4.
go back to reference Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417CrossRef Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417CrossRef
5.
6.
go back to reference Vinogradova Y, Hippisley-Cox J, Coupland C (2009) Identification of new risk factors for pneumonia: population-based case-control study. Br J Gen Pract 59:e329–338CrossRef Vinogradova Y, Hippisley-Cox J, Coupland C (2009) Identification of new risk factors for pneumonia: population-based case-control study. Br J Gen Pract 59:e329–338CrossRef
7.
go back to reference Blumentals WA, Arreglado A, Napalkov P, Toovey S (2012) Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord 13:158CrossRef Blumentals WA, Arreglado A, Napalkov P, Toovey S (2012) Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord 13:158CrossRef
8.
go back to reference Koetz K, Bryl E, Spickschen K, O’Fallon WM, Goronzy JJ, Weyand CM (2000) T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci USA 97:9203–9208CrossRef Koetz K, Bryl E, Spickschen K, O’Fallon WM, Goronzy JJ, Weyand CM (2000) T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci USA 97:9203–9208CrossRef
9.
go back to reference Atzeni F, Masala IF, di Franco M, Sarzi-Puttini P (2017) Infections in rheumatoid arthritis. Curr Opin Rheumatol 29:323–330CrossRef Atzeni F, Masala IF, di Franco M, Sarzi-Puttini P (2017) Infections in rheumatoid arthritis. Curr Opin Rheumatol 29:323–330CrossRef
10.
go back to reference Ledingham J, Gullick N, Irving K, Gorodkin R, Aris M, Burke J et al (2017) BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 56:2257CrossRef Ledingham J, Gullick N, Irving K, Gorodkin R, Aris M, Burke J et al (2017) BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 56:2257CrossRef
11.
go back to reference Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I et al (2015) Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet (London, England) 385:1511–1518CrossRef Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I et al (2015) Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet (London, England) 385:1511–1518CrossRef
12.
go back to reference Ni YN, Chen G, Sun J, Liang BM, Liang ZA (2019) The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care (London, England) 23:99CrossRef Ni YN, Chen G, Sun J, Liang BM, Liang ZA (2019) The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care (London, England) 23:99CrossRef
13.
go back to reference Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA et al (2018) Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med 197:757–767CrossRef Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA et al (2018) Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med 197:757–767CrossRef
14.
go back to reference Lee N, Allen Chan KC, Hui DS, Ng EK, Wu A, Chiu RW et al (2004) Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol 31:304–309CrossRef Lee N, Allen Chan KC, Hui DS, Ng EK, Wu A, Chiu RW et al (2004) Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol 31:304–309CrossRef
15.
go back to reference Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P et al (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. https://doi.org/10.1093/cid/ciaa237 Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P et al (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. https://​doi.​org/​10.​1093/​cid/​ciaa237
16.
go back to reference Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ et al (2020) Case of the index patient who caused tertiary transmission of COVID-19 infection in korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 35:e79CrossRef Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ et al (2020) Case of the index patient who caused tertiary transmission of COVID-19 infection in korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 35:e79CrossRef
17.
go back to reference Wang Z, Chen X, Lu Y, Chen F, Zhang W (2020) Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends 14:64–68CrossRef Wang Z, Chen X, Lu Y, Chen F, Zhang W (2020) Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends 14:64–68CrossRef
19.
go back to reference Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395(10229):1033–1034 Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395(10229):1033–1034
20.
go back to reference Shale M, Czub M, Kaplan GG, Panaccione R, Ghosh S (2010) Anti-tumor necrosis factor therapy and influenza: keeping it in perspective. Ther Adv Gastroenterol 3:173–177CrossRef Shale M, Czub M, Kaplan GG, Panaccione R, Ghosh S (2010) Anti-tumor necrosis factor therapy and influenza: keeping it in perspective. Ther Adv Gastroenterol 3:173–177CrossRef
Metadata
Title
Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs
Authors
Jehun Song
Seongmin Kang
Seung Won Choi
Kwang Won Seo
Sunggun Lee
Min Wook So
Doo-Ho Lim
Publication date
01-06-2020
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 6/2020
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-020-04584-7

Other articles of this Issue 6/2020

Rheumatology International 6/2020 Go to the issue